Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
Stock Information for Matinas Biopharma Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.